News

In the latest issue of Frauenheilkunde Aktuell, the biannual magazine of the SGGG (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe; en., Swiss Society of Gynecology and Obstetrics), the society’s president, Professor Michael Mueller, discusses the innovative WID-easy Test with Professor Martin Widschwendter, Director of the Institute for Prevention and Screening (EUTOPS).

Labor Team, the exclusive provider of the WID®-easy test in Switzerland, has launched the test with the support of Prof. Dr. Michael D. Mueller, President of the Swiss Society of Gynaecology and Obstetrics (SGGG), at its annual conference in Interlaken on June 28, 2024.

The WID®-can test is referred to in the scientific literature as the WID-qCIN test and is an epigenetic test for the detection and prediction of cervical cancer.

New data from the EUTOPS team, working with Prof. Joakim Dillner and his team from the Karolinska Institute, has been published in Nature Medicine.

The study investigated whether different sampling methods influence the validity of the WID®-easy test (“WID-qEC test” in the scientific literature)

Dr Chiara Herzog was honored with the “AGO – Young Scientist Award” for the scientific basis of the WID®-easy Test

Martin Widschwendter's research team has developed the non-invasive methylation-based diagnostic WID®-easy test for the early detection of endometrial cancer based on quantitative real-time PCR that can be implemented in diagnostic high-throughput laboratory...

A recent study published in T H E L A N C E T O n c o l o g y demonstrated the ability of the new WID®-easy test to render 90% of surgical diagnostic procedures, e.g., hysteroscopy and curettage, unnecessary in women with abnormal bleeding during or after menopause....

Sola Dx's shareholders, Chiara Herzog and Martin Widschwendter, are making a significant contribution to a new international concept in aging research. In doing so, the researchers are opening up new avenues for the prevention of age-related diseases.Link to the...

Summary Prof Martin Widschwendter, Dr Chiara Herzog and the Team at the European Translational Oncology Prevention & Screening Institute, University of Innsbruck, have developed a new epigenetic test called WID-qEC (brand name: WID®easy) that screens for...

Foundation board member and district governor Michael Brandl, Monika Brandl, Ernst Brandl's widow, award winner Chiara Herzog, Vice Provost of University Innsbruck, Gregor Weihs, and mayor of the city of Schwaz, Mayor Victoria Weber. Dr. Chiara Herzog, head of...

Topics covered are: Unmet needs in cancer prevention P4-medicine The rationale for utilizing DNA-methylation for cancer risk prediction The principle of epigenetic-based risk prediction in surrogate tissue Cell type specificity (epithelial cells vs immune cells)...

The limitations of Polygenic Risk Scores ("PRS") for cancer risk prediction highlight the need for alternative methods that offer higher discriminatory power, prioritize poor prognostic cancers and account for a range of risk factors. Epigenetic-based approaches, such...

Scientists led by Martin Widschwendter (EUTOPS Institute) are developing methods for the early detection of women-specific cancers. With the help of the WID®-tests, epigenetic methods can detect already existing diseases, e.g., endometrial cancer using the...

WID-qEC test was validated in a real-life hospital cohort of 304 women. In addition, a case-control study showed the superiority of the WID-qEC test in the detection of cervical carcinoma, especially endocervical carcinoma, compared to cytological examination.Abstract...

Download the paper here The test was developed using 726 cervicovaginal smears from women with and without endometrial cancer and validated in 562 unrelated cervicovaginal specimens using three different collection methods and two diagnostic and two predictive...